Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Informatics

Exscientia enhances AI with acquisition of Allcyte

by Rick Mullin
June 20, 2021 | A version of this story appeared in Volume 99, Issue 23

A photo of a person looking at a computer screen.
Credit: Allcyte
Allcyte employs more than 25 people at its facility in Vienna.

Exscientia, a British provider of artificial intelligence for drug discovery with its own drug pipeline, will acquire Allcyte, an Austrian developer of AI applications for precision medicine, for about $60 million. Exscientia says the purchase will add the ability to perform high-content evaluation of individual patient biology in primary tumor tissues rather than in artificial cell lines or animal models, allowing integrated drug discovery and patient selection. Exscientia plans to expand Allcyte’s facility in Vienna.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.